FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

B.B. Koolen; K.E. Pengel; J. Wesseling; W.V. Vogel; M.J. Vrancken Peeters; A.D. Vincent; K.G.A. Gilhuijs; S Rodenhuis; E.J. Rutgers; R.A. Valdes Olmos

doi:10.1016/j.breast.2012.12.020

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

Translated title of the contribution: FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

B.B. Koolen, K.E. Pengel, J. Wesseling, W.V. Vogel, M.J. Vrancken Peeters, A.D. Vincent, K.G.A. Gilhuijs, S Rodenhuis, E.J. Rutgers, R.A. Valdes Olmos

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
Original language	Undefined/Unknown
Pages (from-to)	691-697
Number of pages	7
Journal	The Breast
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/j.breast.2012.12.020
Publication status	Published - 2013

Access to Document

10.1016/j.breast.2012.12.020

http://www.ncbi.nlm.nih.gov/pubmed/23414930

Cite this

Koolen, B. B., Pengel, K. E., Wesseling, J., Vogel, W. V., Vrancken Peeters, M. J., Vincent, A. D., Gilhuijs, K. G. A., Rodenhuis, S., Rutgers, E. J., & Valdes Olmos, R. A. (2013). FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. The Breast, 22(5), 691-697. https://doi.org/10.1016/j.breast.2012.12.020

@article{343621773cd54465a61c302197134da5,

title = "FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer",

author = "B.B. Koolen and K.E. Pengel and J. Wesseling and W.V. Vogel and {Vrancken Peeters}, M.J. and A.D. Vincent and K.G.A. Gilhuijs and S Rodenhuis and E.J. Rutgers and {Valdes Olmos}, R.A.",

year = "2013",

doi = "10.1016/j.breast.2012.12.020",

language = "Undefined/Unknown",

volume = "22",

pages = "691--697",

journal = "The Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "5",

}

Koolen, BB, Pengel, KE, Wesseling, J, Vogel, WV, Vrancken Peeters, MJ, Vincent, AD, Gilhuijs, KGA, Rodenhuis, S, Rutgers, EJ & Valdes Olmos, RA 2013, 'FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer', The Breast, vol. 22, no. 5, pp. 691-697. https://doi.org/10.1016/j.breast.2012.12.020

TY - JOUR

T1 - FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

AU - Koolen, B.B.

AU - Pengel, K.E.

AU - Wesseling, J.

AU - Vogel, W.V.

AU - Vrancken Peeters, M.J.

AU - Vincent, A.D.

AU - Gilhuijs, K.G.A.

AU - Rodenhuis, S

AU - Rutgers, E.J.

AU - Valdes Olmos, R.A.

PY - 2013

Y1 - 2013

U2 - 10.1016/j.breast.2012.12.020

DO - 10.1016/j.breast.2012.12.020

M3 - Article

C2 - 23414930

SN - 0960-9776

VL - 22

SP - 691

EP - 697

JO - The Breast

JF - The Breast

IS - 5

ER -